Key Takeaways BCRX is set to report Q2 earnings on Aug. 4, with consensus estimates of $148.85M in sales and $0.03 EPS.Orladeyo sales likely rose on strong prescription trends; label expansion for children under FDA review.SG&A costs expected to rise on global launch activities, while R&D spend declines from pipeline restructuring.BioCryst Pharmaceuticals (BCRX) is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the ...